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Peripheral Calcitonin Gene-Related Peptide Receptor
Activation and Mechanical Sensitization of the
Joint in Rat Models of Osteoarthritis Pain
Craig M. Bullock,1 Peter Wookey,2 Andrew Bennett,3 Ali Mobasheri,4
Ian Dickerson,5 and Sara Kelly1
Objective. To investigate the role of the sensory
neuropeptide calcitonin gene-related peptide (CGRP) in
peripheral sensitization in experimental models of os-
teoarthritis (OA) pain.
Methods. Experimental knee OA was induced in
rats by intraarticular injection of monosodium iodo-
acetate (MIA) or by transection of the medial meniscus
(MMT). Single-unit recordings of joint-innervating no-
ciceptors were obtained in MIA- and saline-treated rats
following administration of CGRP or the CGRP recep-
tor antagonist CGRP 8–37. Effects of CGRP 8–37 were
also examined in rats that underwent MMT and sham
operations. Protein and messenger RNA (mRNA) levels
of CGRP receptor components in the L3–L4 dorsal root
ganglion (DRG) were investigated following MIA treat-
ment.
Results. In both the MIA and MMT groups, the
mechanical sensitivity of joint nociceptors was en-
hanced compared to that in the control groups. Exoge-
nous CGRP increased mechanical sensitivity in a
greater proportion of joint nociceptors in the MIA-
treated rats than in the saline-treated rats. Local block-
ade of endogenous CGRP by CGRP 8–37 reversed both
the MIA- and MMT-induced enhancement of joint
nociceptor responses. Joint afferent cell bodies coex-
pressed the receptor for CGRP, called the calcitonin-
like receptor (CLR), and the intracellular accessory
CGRP receptor component protein. MIA treatment
increased the levels of mRNA for CLR in the L3–L4
DRG and the levels of CLR protein in medium and large
joint afferent neurons.
Conclusion. Our findings provide new and com-
pelling evidence implicating a role of CGRP in peri-
pheral sensitization in experimental OA. Our novel
finding of CGRP-mediated control of joint nociceptor
mechanosensitivity suggests that the CGRP receptor
system may be an important target for the modulation
of pain during OA. CGRP receptor antagonists recently
developed for migraine pain should be investigated for
their efficacy against pain in OA.
Despite pain being the dominant clinical symp-
tom of osteoarthritis (OA), the mechanisms that drive
this pain are poorly understood. The activity-related
pain and distal allodynia associated with OA (1) suggest
that there are alterations in the peripheral and/or central
nociceptive pathways. Joint replacement (2) and intra-
articular local anesthetic (3) are analgesic, highlighting
the importance of peripheral nociceptive mechanisms.
The synovium, ligaments, joint capsule, and subchondral
bone of the knee joint are richly innervated by nocicep-
tors and could be sources of nociceptive input during
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OA (4). Experimental evidence in humans suggests a
sensitization of joint-innervating nociceptors in patients
with symptomatic OA and that this “peripheral sensiti-
zation” makes an important contribution to pain severity
(5). A better understanding of the mechanisms driving
this sensitization would aid the development of im-
proved analgesics.
Accumulating evidence implicates a role of the
sensory neuropeptide calcitonin gene-related peptide
(CGRP) in the peripheral mechanisms of OA pain
(6–11). Multiple knee joint structures are richly inner-
vated by CGRP-expressing sensory neurons (8,12).
Synovial CGRP-immunoreactive nerve fiber density
is greater in OA patients with pain as compared to
asymptomatic controls (6), and the pain localizes to the
joint compartment, exhibiting increased CGRP-
immunoreactive fiber density (7). These clinical findings
demonstrate an association between altered local levels
of CGRP and OA pain. Whether CGRP directly con-
tributes to the augmented peripheral nociceptive inputs
that drive OA pain remains an important unanswered
question that has direct relevance to the treatment of pain.
Intraarticular injection of the chondrocyte me-
tabolism inhibitor monosodium iodoacetate (MIA) and
surgical transection of the medial meniscus (MMT) are
2 commonly used rodent models of OA. Although these
models have different triggering stimuli, both exhibit
joint pathology and pain responses that mirror key
aspects of knee OA in humans (13), providing an
opportunity for furthering our understanding of the
mechanistic aspects of nociception during OA. Weight-
bearing asymmetry in MIA-injected rats is coincident
with sensitized responses of joint C fiber and A fiber
nociceptors (14) and is associated with increased CGRP
expression in joint afferents (8,9). The release of CGRP
from primary afferents increases following MIA (15,16),
and destruction of knee joint CGRP-expressing sensory
terminals prevents the development of MIA-induced
pain (10). These preclinical data together with the
available human data suggest an association between
local CGRP levels, peripheral sensitization, and the
resultant pain of OA, providing strong rationale for
further examining whether a direct relationship exists.
Although CGRP has established roles in central
nociceptive transmission and neurogenic inflammation
in peripheral tissues (17,18), its role in modulating
peripheral nociception is poorly understood. In vivo,
CGRP sensitizes cutaneous nociceptors to noxious stim-
uli, causing pain (19–21), a finding consistent with
reports of CGRP sensitizing sensory neurons in vitro
(22,23). The CGRP receptor consists of the G protein–
coupled receptor (GPCR) calcitonin-like receptor
(CLR), which requires 2 accessory proteins to fully
function, receptor activity–modifying protein 1 (RAMP-
1), which confers pharmacologic specificity, and an
intracellular CGRP receptor component protein
(CRCP), which couples CLR to intracellular signaling
pathways (24). All 3 components are expressed in dorsal
root ganglion (DRG) neurons (25,26). Whether they are
expressed in joint afferents and whether their activation
sensitizes joint nociceptors is unknown.
The aim of this study was to examine whether
CGRP makes an important contribution to the mainte-
nance of peripheral sensitization during experimentally
induced OA. Given the recent success of CGRP recep-
tor antagonists in trials of patients with migraine pain
(27), studies aimed at answering this question are ex-
tremely timely (28). The ability of CGRP to sensitize
mechanoreceptive joint-innervating nociceptors and the
effects of blocking the action of local endogenous CGRP
on established joint nociceptor sensitization was investi-
gated in the MIA model. To assess the physiologic
relevance of our findings, we also determined the effects
of CGRP receptor blockade in the MMT model. The
impact of MIA-induced OA on CGRP receptor compo-
nent at the protein and messenger RNA (mRNA) levels
in the L3–L4 DRG was determined.
MATERIALS AND METHODS
Drugs. Sodium pentobarbital (Sigma, UK) was dis-
solved in 10% ethanol, 20% propylene glycol, and 70% saline.
MIA (Sigma), rat -CGRP (Sigma), rat CGRP 8–37 (Tocris
Bioscience), and 2% Fluoro-Gold (Fluorochrome) were dis-
solved in sterile saline. Antibodies were prepared in antibody
diluent (Dako).
Animals and induction of OA. Procedures were carried
out in accordance with the UK Animals (Scientific Procedures)
Act 1986 and the Animals in Research: Reporting In Vivo
Experiments (ARRIVE) guidelines (29). A total of 109 male
Sprague-Dawley rats (Charles River UK) ages 5–7 weeks and
weighing 152–289 gm were used in these experiments. Rats
were anesthetized with 3% isoflurane in O2, and OA was
induced in the left knee joint by a single intraarticular injection
of MIA (1 mg in 50 l of sterile saline; n  48 rats) or by
transection of the medial meniscus (n  8 rats) as described
previously (30). Control rats received an intraarticular injec-
tion of saline (50 l; n  47 rats) or underwent sham surgery
(n  6 rats).
Behavioral testing. Baseline pain behavior was as-
sessed on day 0 (immediately prior to OA induction) and up to
day 14 following MIA/saline injection or days 14–18 following
MMT/sham surgery (immediately prior to electrophysiology or
perfusion).
Effects on weight bearing in the ipsilateral and con-
tralateral hind limbs were assessed using an incapacitance
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tester (Linton Instrumentation) as described elsewhere (14).
Data are expressed as ipsilateral weight bearing, which was
calculated as a percentage of total hind limb weight bearing.
Surgical preparation for electrophysiology. The surgi-
cal preparation methods were similar to those described
elsewhere (14). Fourteen days post-MIA/saline injection or
14–18 days post-MMT/sham surgery, anesthesia was induced
with sodium pentobarbital (50–60 mg/kg intraperitoneally) or
isoflurane (3% in O2; 1.5 liters/minute) and maintained with
sodium pentobarbital (20–35 mg/kg/hour intravenously). Core
body temperature (36.5–37.5°C) was maintained. In some rats
(CGRP experiments; n  20), the left carotid artery was
cannulated (SensoNor 840 cannula) for monitoring of the
mean arterial blood pressure.
Extracellular recordings of knee joint nociceptor ac-
tivity. Rats were prepared for joint nociceptor recordings as
described previously (14). The skin and connective tissue
overlying the knee joint were incised, and the medial aspect of
the joint was exposed. Mechanosensitive knee joint nocicep-
tors of the saphenous nerve were identified by probing the
subcutaneous structures over and around the exposed knee
joint, using a 15-gm von Frey monofilament. Nerve filaments
were teased until 1–3 single units could be identified and
sorted offline (CED Spike2 software); firing frequencies
evoked by trains of von Frey monofilaments (0.16–15 gm for 5
seconds for each monofilament, with 5 minutes between trains)
of the most reliable unit were quantified until stable; 1 fiber
per rat was studied.
Drugs were then administered via a cannula into the
contralateral femoral artery, with the tip placed at the bifur-
cation of the descending aorta for semilocal, close intraarterial
injection into the ipsilateral hind limb. The effects of rat
-CGRP (0.5 or 1 g/100 l per unit; n  20) or the CGRP
receptor antagonist rat CGRP 8–37 (5 or 10 g/100 l per unit;
n  31) on mechanical evoked responses (0.16–15 gm for 5
seconds each at 5-minute intervals and at 60 minutes per dose)
were recorded. In vehicle experiments (n  12), two 100-l
injections of saline were administered; thus, the recording
period was identical to that for the drug experiments.
Data were recorded using a Micro 1401 data acquisi-
tion unit (CED) and were captured by a computer running
CED Spike2 software. Conduction velocities of recorded units
were estimated from conduction latency values recorded be-
tween electrical monopolar stimulation (up to 30V for 0.5 msec
at 0.3 Hz) of their receptive field and the onset of evoked
action potentials, and conduction distances were estimated
along the nerve between the stimulation and recording sites
(31). C fibers and A fibers had conduction velocities of 1.3
meters/second and 1.3–15 meters/second, respectively (31).
KCl (100 l of a 250 mM preparation) was administered
intraarterially (contralateral femoral artery) to confirm that
the drugs reached the peripheral afferent terminals; afferents
not activated were excluded. The mechanical threshold was
calculated as the minimum von Frey monofilament weight that
evoked 2 action potentials.
TaqMan real-time quantitative polymerase chain re-
action (qPCR) analysis. Total RNA was extracted from the
L3–L4 ipsilateral DRG obtained on day 14 and 28 from MIA-
or saline-treated rats, snap frozen, homogenized in 0.5 ml of
ice-cold TRI Reagent (Sigma), and purified according to the
manufacturer’s instructions. For complementary DNA
(cDNA) synthesis, 100 ng of total RNA was reverse transcribed
using an AffinityScript cDNA synthesis kit (Agilent) in a 20-l
total reaction volume. Reaction volumes were incubated for 10
minutes at 25°C followed by 1 hour at 50°C and terminated by
incubation for 15 minutes at 70°C. Gene expression was
quantified by the relative standard curve method using Taq-
Man real-time qPCR, as described previously (32). Threshold
cycles were normalized to those of the housekeeping gene
-actin to obtain relative expression levels. Primers and probes
(FAM or TAMRA modified) were designed using Primer
Express v3 software (Applied Biosystems) and synthesized by
Eurofins MWG (Table 1).
Fluoro-Gold labeling of knee joint afferents. Seven
days prior to MIA/saline injection, rats (n  8 per group) were
anesthetized with isoflurane (3% in O2) and 5 l of 2%
Fluoro-Gold (Fluorochrome) was injected into the left knee
joint. Fourteen days post-MIA/saline (21 days after Fluoro-
Gold injection), rats were perfused transcardially with 4%
paraformaldehyde (PFA) and L3 through L5 DRGs were
collected, postfixed overnight in PFA, and cryoprotected in
30% sucrose overnight. DRGs were rapidly frozen over liquid
nitrogen–cooled isopentane in OCT compound (VWR) and
stored at 80°C. Ipsilateral L4 DRGs were cryosectioned (13
m) onto Superfrost Plus slides (Fisher Scientific) and stored
at 20°C. DRGs were serially sectioned over 8 slides; each
slide contained 6–9 sections per DRG, each separated by 8
sections (104 m), ensuring that each cell was counted once.
One slide per DRG was used for immunohistochemical stain-
ing, and cell counts were performed on 5 sections per slide.
Immunohistochemistry. Ipsilateral L4 DRG sections
from MIA- and saline-treated rats were blocked with 5%
normal donkey serum then incubated with a mouse monoclo-
nal (IgG1) anti-CLR antibody (1:250 dilution; Welcome Re-
ceptor Antibodies). Slides were incubated with a rabbit poly-
clonal anti–neuronal nuclei (anti-NeuN) antibody (1:300
dilution; Millipore) or an affinity-purified rabbit polyclonal
anti-CRCP antibody NY1047 (1:500 dilution). Immunoreactiv-
ity of CLR, NeuN, and CRCP were determined by incubation
with Alexa Fluor 488–labeled donkey anti-mouse IgG (1:1,000
dilution; Invitrogen) and Alexa Fluor 568–labeled donkey
anti-rabbit IgG (1:1,000 dilution for NeuN and 1:600 dilution
for CRCP; Invitrogen), respectively. Slides were mounted with
Fluoromount (Sigma). Negative controls included omission of
primary antibodies or incubation with a nonspecific mouse
IgG1 for CLR (1:250 dilution; Dako).
Images were captured on a Leica DMIRB fluorescence
microscope at 20 magnification and acquired using Openlab
software (PerkinElmer) controlling a Hamamatsu Orca
C4642-95 camera. Image analysis and cell counts were per-
formed offline using SimplePCI (Hamamatsu). Somata mea-
suring 30 m, 30–40 m, and 40 m in diameter were
considered small, medium, and large, respectively (9).
Statistical analysis. Data were analyzed using Graph-
Pad Prism software version 5/6 and were tested for normality
using the Kolmogorov-Smirnov test. Where appropriate, para-
metric statistics were used. Any data not normally distributed
were analyzed using nonparametric tests. Two-way analysis of
variance (ANOVA) with Bonferroni post hoc test was used to
compare multiple groups and variables in the behavioral and
electrophysiologic data. Mann-Whitney t-tests were used to
compare mechanical thresholds, immunohistochemical data,
2190 BULLOCK ET AL
and mRNA expression data. Fisher’s exact test was used to
compare contingency tables (2  2). Data are expressed as
described below. P values less than 0.05 were considered
significant.
RESULTS
Pain behavior evoked by MIA injection and
MMT surgery. Weight-bearing analysis confirmed OA
pain development. As previously described (14,33,34),
there was a significant reduction in weight bearing on
the ipsilateral hind limb in MIA-injected rats compared
to saline-injected rats on days 3, 7, and 14 (P  0.001 by
two-way ANOVA with Bonferroni post hoc test). Imme-
diately prior to electrophysiology (day 14), ipsilateral
weight bearing in MIA-treated rats was 39.29  0.71%
(mean  SEM) compared to 49.09  0.16% in saline-
treated rats (P  0.001 by two-way ANOVA with
Bonferroni post hoc test).
Overall, MMT surgery resulted in a modest but
significant reduction in ipsilateral hind limb weight
bearing as compared to sham surgery (P  0.01 by
two-way ANOVA). On day 8 post-MMT, ipsilateral
weight bearing was 43.68  1.12%, as compared to
47.46  0.65% in sham-operated rats (P  0.01 by
two-way ANOVA with Bonferroni post hoc test). Imme-
diately prior to electrophysiology (days 14–18), there
was no significant difference between the MMT and
sham-operated groups (45.97  0.42% versus 46.45 
0.90%); however, in both groups, weight bearing was
significantly reduced compared to day 0 (50.19  0.22%
[P  0.001 by two-way ANOVA with Tukey’s post hoc
test] and 49.98  0.25% [P  0.01], respectively).
Mechanically sensitized joint nociceptors in OA
models. Sixty-three joint nociceptors (n  25 MIA-
treated, n  24 saline-treated, n  8 MMT-operated,
and n  6 sham-operated rats) were studied. The range
of conduction velocities was similar in MIA- and saline-
treated rats (0.39–13.1 meters/second [median 1.4] and
0.3–13.6 meters/second [median 1.7]) as well as in
MMT- and sham-operated rats (1.2–3.3 meters/second
[median 1.93] and 0.99–7.67 meters/second [median
1.73]). All fibers were either C fibers (1.3 meters/
second) or A fibers (1.3–15 meters/second). Conduc-
tion velocities were unidentified in 10 fibers.
Fourteen days post-MIA and 14–18 days post-
MMT, mechanical evoked responses (0.16–15 gm mean
firing rates) of joint nociceptors were significantly in-
creased compared to control responses, with a mean 
SEM area under the curve (AUC) of 65.13  5.94 in
MIA-treated rats versus 41.36  3.95 in saline-treated
rats (P  0.01 by unpaired t-test) and a mean AUC of
49.50  4.62 in MMT rats versus 32.93  2.37 in
sham-operated rats (P  0.01 by unpaired t-test). For
example, firing rates evoked by 8 gm of mechanical
stimulation in MIA-treated rats (mean  SEM 11.96 
0.76 impulses/second) and by 10 gm of stimulation in
MMT rats (8.53  0.94 impulses/second) were signifi-
cantly greater than those in control rats (9.89  0.62
Table 1. Primer and probe sequences used for the TaqMan real-time quantitative polymerase chain
reaction analyses
Gene, NCBI
accession no. Primer strand/probe sequence
CLR
NM_012717 Forward: TGTACACTATGTTTTCTGTTTCTCTTGCT
Reverse: TTTGGTTCGCGCCTTCTT
Probe: CTTAATATGGCTCTCATCGCAGCAGAGTCG
RAMP1
NM_031645 Forward: GCTGCTGGCTCATCATCTCTT
Reverse: TGGTCTCCATGTCCTCTTTGAA
Probe: TACTCTCATCCAGGAGCTGTGTCTCAGCC
RCP
NM_053670 Forward: CCATCACCTACGAGACATTAAAATACA
Reverse: TCTTCATTGCTGTGAGGAATTCTT
Probe: AAACTCCATGTAAGAACCAGAGTCCGGCG
-CGRP
NM_001033955 Forward: TTGTCAGCATCTTGCTCCTGTAC
Reverse: GCCTGGGCTGCTTTCCA
Probe: TCCAGGCAGTTCCTTTGAGGTCAACC
-actin
NM_031144 Forward: GGCCATGTACGTAGCCATCCA
Reverse: TCTCCGGAGTCCATCACAATG
Probe: GTCCCTGTATGCCTCTGGTCGTACCAC
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impulses/second in saline-treated rats and 5.97  0.28
impulses/second in sham-operated rats; P  0.05 for
each comparison, by unpaired t-test). Mechanical
thresholds were significantly reduced in MIA-treated
rats as compared to saline-treated rats (median 0.6 gm
[range 0.16–4] and median 1.0 gm [range 0.16–6]; P 
0.001 by Mann-Whitney t-test). Although mechanical
thresholds were reduced in MMT rats compared to
sham-operated rats, the difference was not significant
(median 0.16 gm [range 0.16–2] versus median 0.5 gm
[range 0.16–2]). Data in the MIA-treated rats were
consistent with published data (14). This is therefore the
first report of the sensitizing effect of MMT on the
mechanical sensitivity of joint nociceptors.
CGRP sensitization of an increased proportion
of joint nociceptors to mechanical stimuli following MIA
treatment. To determine whether exogenous CGRP
affects knee joint nociceptor mechanical sensitivity and,
Figure 1. Calcitonin gene-related peptide (CGRP)–induced mechanical sensitization of an increased proportion of knee afferents following
monosodium iodoacetate (MIA) injection. A and B, CGRP significantly increased the mechanical evoked firing rates (action potentials per second
[APs/s]) of joint afferents in saline-treated (A) and MIA-treated (B) rats (P  0.001 by 2-way analysis of variance with Bonferroni post hoc test).
Values are the mean SEM maximum sensitizing effects of CGRP over each 1-hour recording period (n 9 MIA-treated rats; n 5 saline-treated
rats). C, CGRP administration reduced mechanical thresholds (minimum stimulus evoking 2 action potentials) in saline-treated rats to a level not
significantly different from that in MIA-treated rats (P 0.05 for comparisons of 0.5 g or 10 g of CGRP versus controls, by Mann-Whitney t-test).
Mechanical thresholds in MIA-treated rats were unaltered by CGRP administration. Each circle represents an individual rat (n  7–9 MIA treated
and n  5 saline treated); horizontal lines show the median. D, The percentage of fibers sensitized by CGRP was greater in MIA-treated rats than
in saline-treated rats (P  0.001 by Fisher’s exact test).   P  0.05;   P  0.01;   P  0.001 by Mann-Whitney t-test. vFH  von Frey
hair; NS  not significant.
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if so, whether this is influenced by OA development,
mechanically evoked responses were studied in MIA-
treated and saline-treated rats following CGRP admin-
istration. CGRP significantly increased mechanical
evoked responses of joint nociceptors to a similar degree
in MIA- and saline-treated rats (P  0.001 by two-way
ANOVA) (Figures 1A and B). The lowered mechanical
thresholds of joint nociceptors in MIA-treated rats were
not significantly affected by CGRP, while mechanical
thresholds in saline-treated rats were reduced to a level
similar to those in the MIA-treated rats (Figure 1C).
Although the magnitude of increase in evoked
firing rates caused by CGRP was similar in MIA- and
saline-treated rats, the proportion of fibers affected was
significantly greater following MIA treatment (P 
0.001 by Fisher’s exact test) (Figure 1D). Injection of
vehicle (saline) had no significant effect (data not
shown). CGRP administration had a transient (5 min-
utes) hypotensive effect that was equal in the MIA- and
saline-treated rats (mean  SEM reduction following 1
g of CGRP 40.76  2.77 mm Hg and 39.17  7.84 mm
Hg; P  0.05 by Mann-Whitney t-test). Blood pressure
returned to normal before mechanical stimulation was
started (i.e., within 1 minute).
Reversal of OA-induced mechanosensitization of
joint nociceptors by the CGRP receptor antagonist
CGRP 8–37. We next examined whether endogenous
CGRP contributes to the OA-induced increase in me-
chanical sensitivity of joint nociceptors. The effects of
the CGRP receptor antagonist CGRP 8–37 on enhanced
mechanical evoked responses in the MIA and MMT
models were investigated. Figure 2 illustrates the inhib-
itory effects of CGRP 8–37 on 8–15-gm evoked re-
sponses in an MIA-treated rat as compared to a saline-
treated rat. It is noteworthy that the inhibitory effects
were more pronounced following MIA treatment.
Overall, CGRP 8–37 had no significant effects on
evoked responses of joint nociceptors in control rats,
whether saline-treated (Figure 3A) or sham-operated
(Figure 3D), but significantly and dose-dependently
inhibited responses in MIA-treated (Figure 3B) and
MMT-operated (Figure 3E) rats (P  0.001 for each
comparison, by 2-way ANOVA).The lowered mechani-
cal thresholds in MIA-treated rats were significantly
increased by CGRP 8–37 (P  0.05 by Mann-Whitney
t-test) (Figure 3C) to a similar level as those in the joint
nociceptors in saline-treated rats. Thresholds in saline-
treated rats were unaltered by CGRP 8–37 (Figure 3C).
Although mechanical thresholds in MMT-operated rats
showed a trend toward being increased by CGRP 8–37,
this did not reach significance (Figure 3F), and thresh-
olds were unaltered in sham-operated rats (Figure 3F).
These data indicate that local CGRP receptor blockade
reverses established OA-induced mechanical sensitiza-
tion of joint nociceptors.
Expression of mRNA for the CGRP receptor
component in L3–L4 DRGs from MIA-treated and
saline-treated rats. Since our electrophysiologic data
indicated an enhanced sensitivity of the OA joint to local
CGRP, we examined the expression of transcripts for
CGRP and its receptor components (CLR, RAMP-1,
and CRCP) in the L3–L4 DRG following MIA treat-
ment (14 and 28 days). Using TaqMan quantitative
reverse transcription–PCR (qRT-PCR) analysis (32),
mRNA for CGRP, CLR, RAMP-1, and CRCP were
detected in L3–L4 DRGs from MIA- and saline-treated
Figure 2. Inhibition of knee afferent mechanical evoked firing by the
calcitonin gene-related peptide (CGRP) receptor antagonist CGRP
8–37 in monosodium iodoacetate (MIA)–treated rats. Representative
examples of knee afferent mechanical evoked (8-, 10-, or 15-gm von
Frey monofilaments) response data recorded before and after admin-
istration of 10 g of CGRP 8–37 in a saline-treated rat (A) and an
MIA-treated rat (B) are shown. The inhibitory effects of CGRP 8–37
were more pronounced following MIA treatment. Results are repre-
sented as rate histograms (1-second bins) of action potential firing of
knee afferents (single units) in response to stimulation at the indicated
von Frey monofilament level. Insets show an overlay of a representa-
tive fiber recording with the corresponding conduction velocity (CV; in
meters/second), demonstrating single-fiber recordings; both are A
fibers.
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rats (Figures 4A–D) confirming that mRNA for CGRP
and its receptor components are expressed in DRGs at
levels that contain the cell bodies of knee joint nocice-
ptors. At 14 days, the levels of mRNA for CGRP, CLR,
and RAMP-1 (Figures 4A–C) were not appreciably
altered in the MIA-treated group as compared to the
saline-treated group, whereas the levels of CRCP
mRNA (Figure 4D) were significantly decreased. On
day 28, CGRP mRNA levels were significantly de-
creased, CLR and CRCP were increased, and RAMP-1
Figure 3. Ablation of monosodium iodoacetate (MIA)–induced and medial meniscus transection (MMT)–induced mechanical sensitization of joint
afferents by the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP 8–37. CGRP 8–37 had no effect on mechanically evoked
responses (action potentials per second [APs/s]) of joint afferents in saline-treated (A) and sham-operated (D) rats, whereas it significantly inhibited
mechanically evoked responses in MIA-treated (B) and MMT-operated (E) rats (P  0.0001 for each comparison versus its corresponding control,
by 2-way analysis of variance with Bonferroni post hoc test). Values are the mean  SEM responses over each 1-hour recording period (n  8
saline-treated, 6 sham-operated, 9 MIA-treated, and 8 MMT-operated rats). CGRP 8–37 had no effect on mechanical thresholds (minimum stimulus
evoking2 action potentials) in saline-treated (C) or sham-operated (F) rats. However, in MIA-treated (C) and MMT-operated (F) rats, thresholds
in the presence of 10 g of CGRP 8–37 were increased, reversing the osteoarthritis-induced reduction of mechanical thresholds. Each circle
represents an individual rat (n 6–9 per group); horizontal lines show the median.  P 0.05;  P 0.01;  P 0.001, by Mann-Whitney
t-test. vFH  von Frey hair.
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mRNA levels were unaltered in MIA-treated rats com-
pared to saline-treated rats. These data indicate that
following the development of OA, the expression of
CLR and CRCP in L3–L4 DRGs is regulated.
Coexpression of CLR with CRCP in joint affer-
ents and increased expression following MIA treatment.
Our qRT-PCR data demonstrated that the expression of
mRNA for CGRP and its receptor components is regu-
Figure 4. Expression of mRNA for calcitonin gene-related peptide (CGRP) receptor components in knee joint–innervating L3–L4 dorsal root
ganglia (DRGs) and modulation of the levels following treatment with monosodium iodoacetate (MIA). A, Expression of mRNA for CGRP was
significantly reduced 28 days after MIA treatment. B, Calcitonin-like receptor (CLR) expression was increased 28 days after MIA treatment. C,
Levels of receptor activity–modifying protein 1 (RAMP-1) were unaltered, both on day 14 and on day 28 after MIA treatment. D, Levels of mRNA
for CGRP receptor component protein (CRCP) were reduced 14 days after MIA treatment. There was a small but significant increase in CRCP
expression 28 days after MIA treatment. Results were normalized to -actin expression (which was unchanged between groups and treatments). Data
are shown as box plots. Each box represents the 25th to 75th percentiles (n 6–8 rats per group). Lines inside the boxes represent the median. Lines
outside the boxes represent the 10th and 90th percentiles.   P  0.05;   P  0.01 by Mann-Whitney t-test.
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lated in knee-innervating DRGs during OA. Fluoro-
Gold retrograde labeling of knee afferents (9) combined
with immunohistochemistry were used to investigate
protein expression, specifically, whether joint afferents
express CLR and CRCP and whether CLR expression
by knee afferents is altered following MIA treatment.
The numbers of Fluoro-Gold–labeled knee afferent cell
bodies were consistent with published data (35) and
were not significantly different between MIA-treated
and saline-treated rats (mean  SEM percentage of
whole ganglia 3.47  0.28% and 3.01  0.61%). No
contralateral Fluoro-Gold–labeled cell bodies were
observed, indicating that there was no systemic leakage
of dye.
Consistent with CLR expression in trigeminal
ganglia (36), CLR immunoreactivity was detected pri-
marily in the plasma membrane and cytoplasm of DRG
cell bodies expressing the neuronal marker NeuN (Fig-
ures 5A1 and A2). Occasional CLR-immunoreactive
cells were also Fluoro-Gold–labeled cells (Figure 5A3),
and frequent Fluoro-Gold–labeled cells were CLR im-
munoreactive, indicating robust expression of CLR pro-
Figure 5. Coexpression of the calcitonin gene-related peptide (CGRP) receptor components calcitonin-like receptor (CLR) and receptor
component protein (CRCP [RCP]) by knee afferent neurons and increased CLR expression following treatment with monosodium iodoacetate
(MIA). A1–A4, CLR is expressed on knee afferents (arrows) and non–knee afferent neuronal cell bodies () in ipsilateral L4 dorsal root ganglia
(DRGs). Slides incubated with anti–neuronal nuclei (anti-NeuN) antibodies or with Fluoro-Gold (FG) are also shown. Bar  34 m. B1–B4, CRCP
is coexpressed with CLR on knee afferent neurons (arrows) and non–knee afferent neurons (). Bar  40 m. C, The numbers of medium (30–40
m in diameter) and large (40–50 m in diameter) CLR-positive knee afferents were significantly increased in MIA-treated rats. CLR-positive knee
afferent cell counts were analyzed according to diameter ranges similar to those described in a previously published report (9). Values are the
mean  SEM of 7 rats per group.   P  0.05 by Mann-Whitney t-test.
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tein in knee afferents (Figure 5A4). Consistent with
previously published data (25), CRCP immunoreactivity
was detected in the cytoplasm, plasma membrane, and
nucleus of L4 DRG neurons (Figure 5B1). As with CLR,
CRCP-expressing cells were Fluoro-Gold–labeled (Fig-
ure 5B3), indicating expression of CRCP protein in knee
afferents (Figure 5B4).
Due to the complex nature of the CGRP recep-
tor, expression of CLR alone does equate to the
presence of functional CGRP receptors; thus, we inves-
tigated whether CLR is coexpressed with CRCP. Fluoro-
Gold–labeled cells showed both CRCP immuno-
reactivity and CLR immunoreactivity (Figures 5B1 and
B2), indicating coexpression in knee afferent neurons
(Figure 5B4). These qualitative observations were made
in L4 DRGs from MIA- and saline-treated rats; no
quantification was attempted in this experiment.
In assessing the impact of experimentally induced
OA on joint afferent expression of CGRP receptor
components, we focused on CLR, the GPCR component
of the CGRP receptor. The percentage of total cells
(whole ganglion) expressing CLR was not altered fol-
lowing MIA treatment (mean  SEM 53.63  6.18%
versus 59.55  4.39% following saline treatment). The
percentage of Fluoro-Gold–labeled knee afferents ex-
pressing CLR showed a tendency to increase following
MIA treatment, although this increase did not quite
reach significance (66.40  7.92% versus 58.98  4.23%
in following saline treatment; P  0.091 by unpaired
t-test). When the numbers of knee afferent neurons
showing CLR staining were analyzed based on cell
diameter (cell diameter being related to function), a
significant increase in the numbers of medium (30–40
m) and large (40 m) knee afferents expressing CLR
was observed following MIA treatment (P  0.05 by
Mann-Whitney t-test) (Figure 5C).
DISCUSSION
CGRP is synthesized and stored in sensory neu-
rons and has known actions as a potent vasodilator and
neuromodulator, in particular playing a key role in
neurogenic inflammation (37). CGRP is implicated in
the generation of migraine pain (28) and inflammatory
joint pain (11), and there are now strong clinical and
preclinical associations between the levels of CGRP in
joints and pain during OA. Whether a direct relationship
or integrated, causal mechanism exists is unknown.
Animal models of OA feature several common
histopathologic features of human OA (14,32) and re-
spond to the analgesics commonly used to treat OA pain
in humans (14,30,38). To this end, rat models of OA
represent important translational research tools with
which to investigate the pathophysiologic mechanisms of
OA pain, and such models provide an opportunity for
the investigation of CGRP-mediated pain mechanisms
that cannot be achieved in humans.
We report herein new evidence that CGRP plays
a critical role in peripherally driven pain mechanisms in
experimental models of OA. Important experimental
outcomes of our study were the demonstration that
CGRP was able to acutely sensitize the responses of
joint nociceptors to mechanical stimulation of the joint
and that local blockade of the effects of CGRP com-
pletely reversed the mechanical sensitization caused by
MIA injection. Importantly, the chemical MIA and
surgical MMT models responded similarly to local
CGRP receptor antagonism. Thus, despite their differ-
ent precipitants/etiologies, our data suggest a common
pathophysiologic pathway involving CGRP that contrib-
utes to the enhancement of nociceptive drive from the
OA joint in these models. A recent study in the MIA
model demonstrated a reversal of weight-bearing asym-
metry following systemic administration of the nonpep-
tide CGRP antagonist BIBN4096BS (11); pharmacoki-
netic data implicated a peripheral site of action. Our
data suggest that the periphery is a critical site for
CGRP receptor blockade–induced analgesia. Accumu-
lating evidence is supportive; rat and mouse models of
OA pain are associated with increased joint afferent
expression of CGRP (8) and increased CGRP release
(15,16), changes coincident with our demonstration of
OA-induced mechanical sensitization of joint nocicep-
tors (14).
Functional deactivation of knee joint CGRP-
expressing sensory terminals prevents the development
of MIA-induced pain behavior (10). Although these
reported effects may not be solely attributable to CGRP,
we have provided substantive evidence that local CGRP
plays a pivotal role in the sensitization of joint nocicep-
tors in 2 distinct models of OA pain. Acute blockade of
joint CGRP receptors by CGRP 8–37 normalized the
enhanced mechanical evoked responses of joint noci-
ceptors in the MIA and MMT models, with no effects in
the respective control groups. Activation of local CGRP
receptors by exogenous CGRP sensitized a significantly
greater number of joint nociceptors in MIA-treated rats
than in saline-treated rats.
Our data suggest that the OA joint exhibits
increased sensitivity to the pronociceptive effects of
CGRP and that this increased CGRP receptor signaling
acts to maintain joint nociceptor sensitization. This
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prompted us to investigate whether CGRP receptor
expression is regulated at this level in the MIA model.
The CGRP receptor comprises the GPCR CLR and the
accessory proteins RAMP-1 and CRCP; however, reli-
able and well-characterized antibodies against RAMP-1
for use in immunohistochemical analysis are not avail-
able. The strategy adopted herein was to investigate
CGRP receptor expression in L3–L4 DRGs by use of
qPCR to analyze CLR, CRCP, and RAMP-1 transcript
levels and by use of immunohistochemistry, with colo-
calization of staining with antibodies against CLR and
CRCP.
The expression of mRNA for CGRP, CLR,
RAMP-1, and CRCP was demonstrated in saline- and
MIA-treated rats. Relative to the reference gene
-actin, significant decreases in the levels of CGRP and
CRCP mRNA were observed in L3–L4 DRGs following
MIA treatment. Although decreased CGRP mRNA
expression is at odds with the reported increases at the
protein level (8,9), a decrease in CGRP mRNA levels
has been reported in MIA and surgical OA models (39).
This may reflect facilitated transport of these transcripts
along the primary afferent axon, with subsequent in-
creased intraaxonal protein expression (40,41) and in-
creased expression at the peripheral terminal. The ob-
served MIA-induced changes in mRNA levels were
small in magnitude, likely reflecting discrete and local-
ized changes specifically in knee afferents, a small but
important population of cells that are not easily detected
with this method. This is supported by our observation of
a significant increase in CLR protein expression in the
L4 DRG that was restricted to cells that innervated the
joint.
Immunohistochemical analysis combined with
retrograde labeling of knee afferents enabled us to
identify colocalization of CLR and CRCP immunoreac-
tivity specifically in these neurons, raising the possibility
of functional CGRP receptors at this level. An increase
in the numbers of medium and large afferents in the
knee, demonstrating CLR immunoreactivity, was ob-
served following MIA, a finding that is consistent with
our demonstration of increased CLR mRNA levels in
MIA-treated rats. MIA treatment has previously been
shown to increase the number of medium and large knee
afferents that express CGRP (9). Together with our
data, these findings suggest that MIA increases CLR and
CGRP expression in an overlapping population of knee
afferents, an intriguing finding given the proposed auto-
receptor role of the CGRP receptor (23,28).
Although coexpression with RAMP-1 is neces-
sary to unequivocally demonstrate the presence of func-
tional CGRP receptors, our demonstration of RAMP-1
mRNA expression in L3–L4 DRGs partially addresses
this issue. Given our electrophysiologic findings of an
increase in the proportion of knee afferents sensitized by
CGRP following MIA treatment, we hypothesize that
this enhanced CLR expression represents, at least in
part, the formation of additional functional CGRP re-
ceptors in joint nociceptors that would be expected to
exacerbate joint nociceptive inputs. Given the high
percentage of knee afferents expressing CGRP (up to
76%) (8) and the CGRP receptor being expressed solely
on CGRP-positive neurons (23), it is highly likely that
knee afferents coexpressing CLR and CRCP also ex-
press CGRP.
Our qPCR and immunohistochemistry data sug-
gest that a direct neuronal mechanism contributes to
CGRP-mediated peripheral sensitization via modulation
of the excitability of joint nociceptor peripheral termi-
nals. Potential cellular mechanisms involved may include
phosphorylation of tetrodotoxin-resistant (TTX-R)
voltage-gated sodium channels (NaV). CGRP enhances
TTX-R NaV currents in DRG neurons in vitro
(22,23,42), lowering the threshold for action potential
generation, a hallmark of peripheral sensitization
(43,44). These in vitro findings are supported by our in
vivo data demonstrating an acute CGRP-evoked reduc-
tion of joint nociceptor mechanical thresholds and a
reversal by CGRP 8–37 of the MIA-induced reduction in
thresholds. This afferent sensitization may in part ac-
count for the acute pronociceptive effects of peripheral
CGRP (37). Injection of CGRP into a joint increases the
expression of phosphorylated forms of the MAP kinases
p38 and ERK in peripheral ganglia, sensitizing nocice-
ptors and enhancing the evoked release of CGRP (45).
Thus, CGRP can initiate acute increases in sensitivity to
sensory stimuli as well as long-term changes in protein
expression in sensory neurons.
It is important to note that CGRP receptors are
also expressed on non-neuronal cells at the level of the
joint within the synovium (46) and on immune and
endothelial cells (47). CGRP plays an important vasodi-
latory role in the joint (48) and is a known immune cell
recruiter, modulating their release of proinflammatory
mediators that are able to directly excite and/or sensitize
sensory neurons (49). Thus, an indirect mechanism
involving these cells types is also likely, although the
relative contribution of neuronal/non-neuronal cells is
unknown.
Our demonstration of a critical involvement of
CGRP in driving the sensitization of the joint in exper-
imental models of OA, along with published clinical
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evidence of an association between joint expression of
CGRP and symptomatic OA in humans emphasizes the
relevance of CGRP to OA pain. Our novel experimental
evidence of an increased functional role of the CGRP
receptor at the level of the joint and our demonstration
that blockade of joint CGRP receptors ablates joint
nociceptor sensitization in models of OA pain support
future targeted site-specific investigations of CGRP
antagonists in the control of pain associated with OA in
humans.
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